Antitumor-kombinationer med et VEGF-hæmmende middel og irinotecan

摘要

Combination (I) comprises vascular endothelial growth factor (VEGF) inhibitor with irinotecan therapeutically used in the treatment of neoplastic diseases. An independent claim is included for a product comprising VEGF inhibitor and irinotecan, as a combined preparation for simultaneous, separated or spread use in the anticancer therapy. ACTIVITY : Cytostatic. MECHANISM OF ACTION : Vascular endothelial growth factor inhibitor; Topoisomerase inhibitor.